aTyr Pharma (LIFE) to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at WMS
Tweet Send to a Friend
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new pathway ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE